Blackstone invests $250 million in Anagram to address cystic fibrosis complication
read at Endpoints ↗DealPositive
Blackstone Life Sciences announced a $250 million investment in Anagram, a biotech focused on cystic fibrosis complications.
The funding is part of one of the largest private investment funds in the sector and is intended to speed up development of therapies aimed at a specific complication of the disease.
The capital will support Anagram's research and clinical programs, with the goal of significantly reducing the burden of cystic fibrosis for patients.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Blackstone puts $250M into Anagram to tackle cystic fibrosis complication”
read at Endpoints ↗78 words · retrieved May 7
comments(0)
5-min edit window · permanent after that